Xtant Medical Holdings (XTNT) Cost of Revenue (2010 - 2025)

Xtant Medical Holdings (XTNT) has 16 years of Cost of Revenue data on file, last reported at $11.3 million in Q3 2025.

• On a quarterly basis, Cost of Revenue fell 3.16% year-over-year to $11.3 million in Q3 2025; TTM through Sep 2025 was $50.5 million, a 13.49% increase from a year earlier, with the FY2024 full-year figure at $49.1 million, up 36.88% from the prior year.
• Cost of Revenue for Q3 2025 stood at $11.3 million, up from $11.1 million in the prior quarter.
• Over the last five years, Cost of Revenue for XTNT reached as high as $15.5 million in Q4 2024 and fell as low as $4.5 million in Q1 2021.
• Historically, Cost of Revenue has averaged $8.9 million across 5 years, with a median of $7.8 million in 2023.
• Across the five-year window, Cost of Revenue slipped 13.82% in 2021 and soared 57.54% in 2023, its largest moves.
• Year by year, Cost of Revenue stood at $6.3 million in 2021, then grew by 10.98% to $7.0 million in 2022, then surged by 57.54% to $11.0 million in 2023, then jumped by 41.18% to $15.5 million in 2024, then slipped by 27.28% to $11.3 million in 2025.
• Per Business Quant data, the three most recent Cost of Revenue figures were $11.3 million in Q3 2025, $11.1 million in Q2 2025, and $12.7 million in Q1 2025.